Literature DB >> 8733121

Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA.

C Huxley1, E Passage, A Manson, G Putzu, D Figarella-Branger, J F Pellissier, M Fontés.   

Abstract

Construction of animal models of human inherited diseases is particularly important for testing gene therapy approaches. Towards this end, we constructed a mouse model for Charcot-Marie-Tooth disease type 1A by pronuclear injection of a YAC containing the human PMP22 gene. In one transgenic line, the YAC DNA is integrated in about eight copies and the PMP22 gene is strongly expressed to give a peripheral neuropathy closely resembling the human pathology. The disorder is dominant, causes progressive weakness of the hind legs, and there is severe demyelination in the peripheral nervous system including the presence of onion bulb formations. This approach will be valuable for pathologies produced by over-expression of a gene including trisomy and amplification in cancer. Such models will be particularly useful for testing gene therapy approaches if the transgene is human.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8733121     DOI: 10.1093/hmg/5.5.563

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  56 in total

1.  Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice.

Authors:  Sunitha Rangaraju; Jonathan D Verrier; Irina Madorsky; Jessica Nicks; William A Dunn; Lucia Notterpek
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

2.  Therapeutic strategies for the inherited neuropathies.

Authors:  Michael E Shy
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 3.  Genetic aspects of Charcot-Marie-Tooth disease.

Authors:  C Bell; N Haites
Journal:  Arch Dis Child       Date:  1998-04       Impact factor: 3.791

Review 4.  Charcot-Marie-Tooth disease: lessons in genetic mechanisms.

Authors:  J R Lupski
Journal:  Mol Med       Date:  1998-01       Impact factor: 6.354

Review 5.  Size matters: use of YACs, BACs and PACs in transgenic animals.

Authors:  P Giraldo; L Montoliu
Journal:  Transgenic Res       Date:  2001-04       Impact factor: 2.788

6.  PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models.

Authors:  Hien Tran Zhao; Sagar Damle; Karli Ikeda-Lee; Steven Kuntz; Jian Li; Apoorva Mohan; Aneeza Kim; Gene Hung; Mark A Scheideler; Steven S Scherer; John Svaren; Eric E Swayze; Holly B Kordasiewicz
Journal:  J Clin Invest       Date:  2017-12-04       Impact factor: 14.808

Review 7.  The PMP22 gene and its related diseases.

Authors:  Jun Li; Brett Parker; Colin Martyn; Chandramohan Natarajan; Jiasong Guo
Journal:  Mol Neurobiol       Date:  2012-12-07       Impact factor: 5.590

8.  Charcot-marie-tooth disease: seventeen causative genes.

Authors:  Jung-Hwa Lee; Byung-Ok Choi
Journal:  J Clin Neurol       Date:  2006-06-20       Impact factor: 3.077

9.  Copy number variation upstream of PMP22 in Charcot-Marie-Tooth disease.

Authors:  Marian A J Weterman; Fred van Ruissen; Marit de Wissel; Lou Bordewijk; Johnny P A Samijn; W Ludo van der Pol; Farid Meggouh; Frank Baas
Journal:  Eur J Hum Genet       Date:  2009-11-04       Impact factor: 4.246

10.  Functional and comparative genomics analyses of pmp22 in medaka fish.

Authors:  Junji Itou; Mikita Suyama; Yukio Imamura; Tomonori Deguchi; Kazuhiro Fujimori; Shunsuke Yuba; Yutaka Kawarabayasi; Takashi Kawasaki
Journal:  BMC Neurosci       Date:  2009-06-17       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.